Alvotech and STADA add to strategic alliance through denosumab partnership [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
This partnership for the osteoporosis and cancer-related molecule builds on the two company's existing strategic alliance in Europe. The first product launched through the alliance was Hukyndra ® , a high-concentration biosimilar to Humira ® (adalimumab) Extended alliance comes as the partners prepare to launch Uzpruvo ® , a biosimilar to Stelara ® (ustekinumab) in Europe following the expiry of applicable intellectual-property rights REYKJAVIK, Iceland and BAD VILBEL, Germany, June 11, 2024 (GLOBE NEWSWIRE) -- Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia ® /Xgeva ® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively. Under the terms of the agreement, Alvotech will be responsible for development and manufacturing at its state-of-the-art facility in Reykjavik, Iceland. STADA
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe [Yahoo! Finance]Yahoo! Finance
- Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in EuropeGlobeNewswire
- Alvotech and Stada add to strategic alliance through denosumab partnership [Seeking Alpha]Seeking Alpha
- Alvotech and STADA add to strategic alliance through denosumab partnershipGlobeNewswire
- Alvotech enters refinancing agreement with $965M term loan facility [Seeking Alpha]Seeking Alpha
ALVO
Earnings
- 5/21/24 - Miss
ALVO
Sec Filings
- 6/18/24 - Form 6-K
- 6/14/24 - Form 6-K
- 6/14/24 - Form 424B5
- ALVO's page on the SEC website